NASDAQ · ARWR

Arrowhead Research Corporation

$85.60 -$1.18 (-1.36%) 1D After hours

Key Metrics

$12.22B
Market cap
P/E · TTM
$622.01M
Revenue · TTM
−$300.91M
Net income
EPS · TTM $-2.15
Dividend yield
Free cash flow −$50.87M
Beta · 1Y 1.54
EBITDA · TTM −$229.76M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 22
    The stock moved +19.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 22
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 10
    The stock moved -9.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 10

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$12.22B
Enterprise value
Shares outstanding140.9M
52-wk range$15.01 – $95.49
Avg volume · 20D1.3M
Net cash
Book value / share$4.39
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Arrowhead Research Corporation
IPO dateFeb 1, 1995
Employees711

Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S19.65
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -40.6%
Net -48.4%
FCF -8.2%
ROE / ROIC -49.0% · 27.7%

Financial Health

Current ratio6.23
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$1.54B

Cash Flow · TTM

Operating CF −$36.31M
Capex −$14.57M
Free cash flow −$50.87M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings